Urpilainen E, Ahtikoski A, Arima R, Puistola U and Karihtala P (2021) No Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes. Front. Pharmacol. 12:621180. doi: 10.3389/fphar.2021.621180
No association between statin use and the prognosis of endometrial cancer in women with type 2 diabetes
|Author:||Urpilainen, Elina1; Ahtikoski, Anne2; Arima, Reetta3;|
1PEDEGO Research Unit, Medical Research Center Oulu, Department of Obstetrics and Gynecology, Oulu University Hospital and University of Oulu, Oulu, Finland
2Cancer and Translational Medicine Research Unit, Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland
3Department of Obstetrics and Gynecology, Central Finland Central Hospital, Jyväskylä, Finland
4Department of Oncology, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 1.2 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2021091646388
|Publish Date:|| 2021-09-16
Preclinical studies have suggested statins have antiproliferative and anti-metastatic effects on endometrial cancer cells. Similarly, most previous epidemiological studies have reported a better prognosis of endometrial cancer in patients who used statins. In this study, we explored the role of statins in the prognosis of endometrial cancer in women with type 2 diabetes in a hospital-based cohort. This retrospective cohort consisted of 119 women with type 2 diabetes who were diagnosed and treated for endometrial cancer at Oulu University Hospital, Finland, between 2007 and 2014. The patients were classified as statin users (n = 58) and nonusers (n = 61) based on the type of medication they were using at the time of endometrial cancer diagnosis. Statin use showed no association with progression-free survival or overall survival in the whole cohort nor the subgroups with type I or type II histology, in lower or higher body mass index groups, or at an early or advanced stage. The results remained similar in the multivariate analysis after adjusting for the patient’s age, cancer stage, and histology. Furthermore, statin use seemed not to have any association with most of the prognostic factors at the time of endometrial cancer diagnosis.
Frontiers in pharmacology
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3123 Gynaecology and paediatrics
This study was funded by grants from the Jane and Aatos Erkko Foundation (T59127) and the Finnish Government Research Funds (K77729) granted to the University Hospital of Oulu.
© 2021 Urpilainen, Ahtikoski, Arima, Puistola and Karihtala. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.